# US 2023/0056252 A1 · Multi-specific antigen binding molecules targeting hiv and methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0056252 A1
- Document ID: US20230056252A1
- Status: Published application
- Kind: A1
- Application number: 17/409,260
- Filed: 2021-08-23
- Published: 2023-02-23
- Earliest claimed: 2020-08-25
- Assignees: Gilead Sciences, Inc.
- Applicants: Gilead Sciences, Inc.
- Inventors: Manuel Baca; Wade S. Blair; Brian A. Carr; Sheila B. Clancy; Joshua Goldsmith; Magdeleine S. Hung; Manu Kanwar; Brian Moldt; Mark Nagel; Craig S. Pace; YenRu Pan; Heather T. Stephenson; Nathan D. Thomsen
- Web page: https://patentgrep.com/patent/US20230056252A1

## CPC

- C07K 16/1145: {Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site}
- A61P 31/18: for HIV
- C07K 14/70514: {CD4}
- C07K 16/2809: {against the T-cell receptor (TcR)-CD3 complex}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/31: multispecific
- C07K 2317/524: CH2 domain
- C07K 2317/526: CH3 domain
- C07K 2317/55: Fab or Fab'
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/71: Decreased effector function due to an Fc-modification
- C07K 2317/72: Increased effector function due to an Fc-modification
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K 2319/00: Fusion polypeptide
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Provided are multi-specific antigen binding molecules, including bispecific antibodies, that bind to CD3 and an HIV antigen, including HIV envelope protein gp120. Also provided are methods of using such antigen binding molecules to treat or prevent HIV infection.

## Claims

### Claim at position 1

1-56. (canceled)

### Claim 57

A multi-specific antigen binding molecule that binds to human CD3 and an HIV antigen, wherein the antigen binding molecule comprises:
(a) a first antigen binding domain that comprises a first heavy chain variable domain (VH) and a first light chain variable domain (VL), wherein the first antigen binding domain binds to CD3 and comprises a first VH-complementarity determining region (CDR) 1, a first VH-CDR2, a first VH-CDR3, a first VL-CDR1, a first VL-CDR2 and a first VL-CDR3 comprising the following amino acid sequences, respectively:
(i) SEQ ID NOs: 1, 11, 8, 4, 9 and 10, or
(ii) SEQ ID NOs: 1, 12, 8, 4, 9 and 10, wherein the CDRs are according to Kabat, and
(b) the second antigen binding domain comprises one or more extracellular (EC) domains of CD4.

### Claim at position 3

58-70. (canceled)

### Claim 71 (depends on 57)

The multi-specific antigen binding molecule of claim 57, wherein the one or more EC domains of CD4 comprise a sequence as set forth below, or a sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to a sequence selected from the group consisting of:
(i)
(SEQ ID NO: 746)
KKVVYGKKGDTVELTCTASQKKNIQFHWKNSNQIKILGNQGSFLTKGPSK
LNDRVDSRRSLWDQGNFPLIIKNLKPEDSDTYICEVEDQKEEVQLVVVG;
(ii)
(SEQ ID NO: 747)
KKVVYGKKGDTVELTCTASQKKNIQFHWKNSNQIKILGNQGSFLTKGPSK
LNDRVDSRRSLWDQGNFPLIIKNLKPEDSDTYICEVEDQKEEVQLVVVGG
GGSGKKVVYGKKGDTVELTCTASQKKNIQFHWKNSNQIKILGNQGSFLTK
GPSKLNDRVDSRRSLWDQGNFPLIIKNLKPEDSDTYICEVEDQKEEVQLV
VVG;
(iii)
(SEQ ID NO: 748)
KKVVLGKKGDTVELTCTASQKKSIQFHWKNSNQIKILGNQGSFLTKGPSK
LNDRADSRRSLWDQGNFPLIIKNLKIEDSDTYICEVEDQKEEVQLLVFG;
or
(iv)
(SEQ ID NO: 749)
KKVVLGKKGDTVELTCTASQKKSIQFHWKNSNQIKILGNQGSFLTKGPSK
LNDRADSRRSLWDQGNFPLIIKNLKIEDSDTYICEVEDQKEEVQLLVFGG
GGSGKKVVLGKKGDTVELTCTASQKKSIQFHWKNSNQIKILGNQGSFLTK
GPSKLNDRADSRRSLWDQGNFPLIIKNLKIEDSDTYICEVEDQKEEVQLL
VFG.

### Claim 72 (depends on 71)

The multi-specific antigen binding molecule of claim 71, wherein the EC domain of CD4 comprises a sequence of SEQ ID NO: 746 or a sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to a sequence of SEQ ID NO: 746.

### Claim at position 6

73-75. (canceled)

### Claim 76 (depends on 71)

The multi-specific antigen binding molecule of claim 71, wherein the first antigen binding domain comprises a first VH-CDR1, a first VH-CDR2, a first VH-CDR3, a first VL-CDR1, a first VL-CDR2 and a first VL-CDR3 comprising the following amino acid sequences, respectively (according to Kabat): SEQ ID NOs: 1, 11, 8, 4, 9 and 10; or SEQ ID NOs: 1, 12, 8, 4, 9 and 10; and the second antigen binding domain comprises one or more EC domains of CD4 comprising an amino acid sequence that comprises or is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%, identical to a CD4 EC domain selected from the group consisting of SEQ ID NOs: 746-749.

### Claim 77 (depends on 76)

The multi-specific antigen binding molecule of claim 76, wherein the first antigen binding domain comprises a first VH-CDR1, a first VH-CDR2, a first VH-CDR3, a first VL-CDR1, a first VL-CDR2 and a first VL-CDR3 comprising the following amino acid sequences, respectively (according to Kabat): SEQ ID NOs: 1, 12, 8, 4, 9 and 10; and the second antigen binding domain comprises one or more EC domains of CD4 comprising an amino acid sequence that comprises or is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%, identical to a CD4 EC domain selected from the group consisting of SEQ ID NO: 746.

### Claim at position 9

78-84. (canceled)

### Claim 85 (depends on 71)

The multi-specific antigen binding molecule of claim 71, wherein the first antigen binding domain comprises a first VH and a first VL comprising the amino acid sequences set forth, respectively, or comprising amino acid sequences that are at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequences set forth, respectively: SEQ ID NOs: 51 and 56; and the second antigen binding domain comprises one EC domain of CD4 comprising an amino acid sequence that comprises or is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%, identical to a CD4 EC domain of SEQ ID NO: 746.

### Claim at position 11

86-100. (canceled)

### Claim 101 (depends on 57)

The multi-specific antigen binding molecule of claim 57, comprising a heterodimeric human IgG1 or IgG4, comprising a first Fc region and a second Fc region.

### Claim at position 13

102-110. (canceled)

### Claim 111 (depends on 57)

The multi-specific antigen binding molecule of claim 57, comprising a heterodimeric human IgG1 or IgG4, comprising a first Fc region and a second Fc region, comprising the following amino acids at the indicated positions (EU numbering):
(i) the first Fc region comprises an alanine at position 234 (L234), an alanine at position 235 (L235A), a serine at position 331 (P331S) and a tryptophan at position 366 (T366W); and the second Fc region comprises an alanine a position 234 (L234), an alanine at position 235 (L235A), a serine at position 331 (P331S), a serine at position 366 (T366S), an alanine at position 368 (L368A), a valine at position 407 (Y407V), and an arginine at position 435 (H435R);
(ii) the first Fc region comprises an alanine at position 234 (L234), an alanine at position 235 (L235A), a serine at position 331 (P331S) and a tryptophan at position 366 (T366W); and the second Fc region comprises an alanine a position 234 (L234), an alanine at position 235 (L235A), a serine at position 331 (P331S), a serine at position 366 (T366S), an alanine at position 368 (L368A), a valine at position 407 (Y407V), an arginine at position 435 (H435R) and a phenylalanine at position 436 (Y436F);
(iii) the first Fc region comprises an alanine at position 234 (L234), an alanine at position 235 (L235A), a serine at position 331 (P331S), a serine at position 366 (T366S), an alanine at position 368 (L368A), and a valine at position 407 (Y407V); and the second Fc region comprises an alanine at position 234 (L234), an alanine at position 235 (L235A), a serine at position 331 (P331S) and a tryptophan at position 366 (T366W);
(iv) the first Fc region comprises an alanine at position 234 (L234), an alanine at position 235 (L235A), a serine at position 331 (P331S), a tryptophan at position 366 (T366W), a leucine at position 428 (M428L) and a serine at position 434 (N434S); and the second Fc region comprises an alanine a position 234 (L234), an alanine at position 235 (L235A), a serine at position 331 (P331S), a serine at position 366 (T366S), an alanine at position 368 (L368A), a valine at position 407 (Y407V), and an arginine at position 435 (H435R); or
(v) the first Fc region comprises an alanine at position 234 (L234), an alanine at position 235 (L235A), a serine at position 331 (P331S), a tryptophan at position 366 (T366W), a tyrosine at position 252 (M252Y), a threonine at position 254 (S254T) and a glutamic acid at position 256 (T256E); and the second Fc region comprises an alanine a position 234 (L234), an alanine at position 235 (L235A), a serine at position 331 (P331S), a serine at position 366 (T366S), an alanine at position 368 (L368A), a valine at position 407 (Y407V), and an arginine at position 435 (H435R).

### Claim 112 (depends on 57)

The multi-specific antigen binding molecule of claim 57, comprising a heterodimeric human IgG1, comprising a first Fc region and a second Fc region, comprising the following amino acids at the indicated positions (EU numbering): the first Fc region comprises an alanine a position 234 (L234), an alanine at position 235 (L235A), a serine at position 331 (P331S), a serine at position 366 (T366S), an alanine at position 368 (L368A), a valine at position 407 (Y407V), and an arginine at position 435 (H435R); and the second Fc region comprises an alanine at position 234 (L234), an alanine at position 235 (L235A), a serine at position 331 (P331S), a tryptophan at position 366 (T366W), a tyrosine at position 252 (M252Y), a threonine at position 254 (S254T) and a glutamic acid at position 256 (T256E).

### Claim 113

(canceled)

### Claim 114 (depends on 111)

The multi-specific antigen binding molecule of claim 111, comprising a heterodimeric human IgG1, comprising a first Fc region and a second Fc region, comprising amino acid sequences of SEQ ID NOs.: 703 and 705, or that are at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequences set forth, respectively: SEQ ID NOs.: 703 and 705.

### Claim at position 18

115-121. (canceled)

### Claim 122

A multi-specific antigen binding molecule that binds to human CD3 and HIV gp120, wherein the antigen binding molecule comprises:
(a) a first antigen binding domain that comprises a first heavy chain variable domain (VH) and a first light chain variable domain (VL), wherein the first antigen binding domain binds to CD3; and
(b) a second antigen binding domain that binds to HIV gp120 comprising one or more extracellular (EC) domain of CD4, wherein the one or more EC domains of CD4 comprise a sequence as set forth below, or a sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to a sequence selected from the group consisting of:
(i)
(SEQ ID NO: 746)
KKVVYGKKGDTVELTCTASQKKNIQFHWKNSNQIKILGNQGSFLTKGPSK
LNDRVDSRRSLWDQGNFPLIIKNLKPEDSDTYICEVEDQKEEVQLVVVG;
(ii)
(SEQ ID NO: 747)
KKVVYGKKGDTVELTCTASQKKNIQFHWKNSNQIKILGNQGSFLTKGPSK
LNDRVDSRRSLWDQGNFPLIIKNLKPEDSDTYICEVEDQKEEVQLVVVGG
GGSGKKVVYGKKGDTVELTCTASQKKNIQFHWKNSNQIKILGNQGSFLTK
GPSKLNDRVDSRRSLWDQGNFPLIIKNLKPEDSDTYICEVEDQKEEVQLV
VVG;
(iii)
(SEQ ID NO: 748)
KKVVLGKKGDTVELTCTASQKKSIQFHWKNSNQIKILGNQGSFLTKGPSK
LNDRADSRRSLWDQGNFPLIIKNLKIEDSDTYICEVEDQKEEVQLLVFG;
or
(iv)
(SEQ ID NO: 749)
KKVVLGKKGDTVELTCTASQKKSIQFHWKNSNQIKILGNQGSFLTKGPSK
LNDRADSRRSLWDQGNFPLIIKNLKIEDSDTYICEVEDQKEEVQLLVFGG
GGSGKKVVLGKKGDTVELTCTASQKKSIQFHWKNSNQIKILGNQGSFLTK
GPSKLNDRADSRRSLWDQGNFPLIIKNLKIEDSDTYICEVEDQKEEVQLL
VFG.

### Claim 123 (depends on 122)

The multi-specific antigen binding molecule of claim 122, wherein the one or more EC domains of CD4 comprise a sequence as set forth below, or a sequence that is at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the sequence of SEQ ID NO: 746.

### Claim 124 (depends on 122)

The multi-specific antigen binding molecule of claim 122, wherein the first antigen binding domain is a Fab and the second antigen binding domain is a scFv or an EC domain of CD4 wherein the first antigen binding domain comprises a first HC and a LC, and the second antigen binding domain comprises a second HC, the second HC, the first HC and the LC comprising the amino acid sequences set forth, respectively, below, or comprising amino acid sequences that are at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequences set forth, respectively, below:
1) SEQ ID NOs: 751, 752 and 753;
2) SEQ ID NOs: 754, 752 and 753;
3) SEQ ID NOs: 755, 756 and 753;
4) SEQ ID NOs: 755, 757 and 753;
5) SEQ ID NOs: 758, 757 and 753;
6) SEQ ID NOs: 759, 756 and 753;
7) SEQ ID NOs: 754, 760 and 761;
8) SEQ ID NOs: 762, 760 and 761;
9) SEQ ID NOs: 751, 763 and 753;
10) SEQ ID NOs: 764, 752 and 753;
11) SEQ ID NOs: 765, 752 and 753;
12) SEQ ID NOs: 766, 767 and 753;
13) SEQ ID NOs: 766, 768 and 753;
14) SEQ ID NOs: 769, 768 and 753;
15) SEQ ID NOs: 770, 767 and 753;
16) SEQ ID NOs: 765, 771 and 761;
17) SEQ ID NOs: 772, 771 and 761;
18) SEQ ID NOs: 774, 775 and 776;
19) SEQ ID NOs: 777, 778 and 776;
20) SEQ ID NOs: 779, 778 and 776;
21) SEQ ID NOs: 779, 780 and 776;
22) SEQ ID NOs: 777, 781 and 776;
23) SEQ ID NOs: 782, 752 and 753;
24) SEQ ID NOs: 783, 752 and 753;
25) SEQ ID NOs: 784, 785 and 753;
26) SEQ ID NOs: 784, 786 and 753;
27) SEQ ID NOs: 787, 786 and 753;
28) SEQ ID NOs: 788, 785 and 753;
29) SEQ ID NOs: 783, 789 and 761;
30) SEQ ID NOs: 790, 789 and 761;
31) SEQ ID NOs: 792, 793 and 794;
32) SEQ ID NOs: 795, 796 and 794;
33) SEQ ID NOs: 797, 796 and 794;
34) SEQ ID NOs: 797, 798 and 794; or
35) SEQ ID NOs: 795, 799 and 794.

### Claim 125 (depends on 122)

The multi-specific antigen binding molecule of claim 122, wherein the first antigen binding domain is a Fab and the second antigen binding domain is a scFv or an EC domain of CD4 wherein the first antigen binding domain comprises a first HC and a LC, and the second antigen binding domain comprises a second HC, the second HC, the first HC and the LC comprising the amino acid sequences set forth, respectively, below, or comprising amino acid sequences that are at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequences set forth, respectively, below:
1) SEQ ID NOs: 751, 752 and 753;
2) SEQ ID NOs: 754, 752 and 753;
3) SEQ ID NOs: 755, 756 and 753;
4) SEQ ID NOs: 755, 757 and 753;
5) SEQ ID NOs: 758, 757 and 753;
6) SEQ ID NOs: 759, 756 and 753;
7) SEQ ID NOs: 764, 752 and 753;
8) SEQ ID NOs: 765, 752 and 753;
9) SEQ ID NOs: 766, 767 and 753;
10) SEQ ID NOs: 766, 768 and 753;
11) SEQ ID NOs: 769, 768 and 753;
12) SEQ ID NOs: 770, 767 and 753;
13) SEQ ID NOs: 777, 778 and 776;
14) SEQ ID NOs: 779, 778 and 776;
15) SEQ ID NOs: 779, 780 and 776;
16) SEQ ID NOs: 777, 781 and 776;
17) SEQ ID NOs: 782, 752 and 753;
18) SEQ ID NOs: 783, 752 and 753;
19) SEQ ID NOs: 784, 785 and 753;
20) SEQ ID NOs: 784, 786 and 753;
21) SEQ ID NOs: 787, 786 and 753;
22) SEQ ID NOs: 788, 785 and 753;
23) SEQ ID NOs: 795, 796 and 794;
24) SEQ ID NOs: 797, 796 and 794;
25) SEQ ID NOs: 797, 798 and 794; or
26) SEQ ID NOs: 795, 799 and 794.

### Claim 126 (depends on 122)

The multi-specific antigen binding molecule of claim 122, wherein the first antigen binding domain is a Fab and the second antigen binding domain is a scFv or an EC domain of CD4 wherein the first antigen binding domain comprises a first HC and a LC, and the second antigen binding domain comprises a second HC, the second HC, the first HC and the LC comprising the amino acid sequences set forth, respectively, below, or comprising amino acid sequences that are at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequences set forth, respectively, below:
1) SEQ ID NOs: 751, 752 and 753;
2) SEQ ID NOs: 754, 752 and 753;
3) SEQ ID NOs: 755, 756 and 753;
4) SEQ ID NOs: 755, 757 and 753;
5) SEQ ID NOs: 758, 757 and 753; or
6) SEQ ID NOs: 759, 756 and 753.

### Claim 127 (depends on 122)

The multi-specific antigen binding molecule of claim 122, wherein the first antigen binding domain is a Fab and the second antigen binding domain is a scFv or an EC domain of CD4 wherein the first antigen binding domain comprises a first HC and a LC, and the second antigen binding domain comprises a second HC, the second HC, the first HC and the LC comprising the amino acid sequences set forth, respectively, below, or comprising amino acid sequences that are at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequences set forth, respectively, below:
1) SEQ ID NOs: 751, 752 and 753; or
2) SEQ ID NOs: 755, 756 and 753.

### Claim 128 (depends on 122)

The multi-specific antigen binding molecule of claim 122, wherein the first antigen binding domain is a Fab and the second antigen binding domain is an EC domain of CD4 wherein the first antigen binding domain comprises a first HC and a LC, and the second antigen binding domain comprises a second HC, the second HC, the first HC and the LC comprising amino acid sequences that are respectively, SEQ ID NOs: 751, 752 and 753, or that are at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequences set forth, respectively: SEQ ID NOs: 751, 752 and 753.

### Claim at position 26

129-131. (canceled)

### Claim 132 (depends on 57)

The multi-specific antigen binding molecule of claim 57, wherein the multi-specific antigen binding molecule is a bispecific antigen binding molecule.

### Claim at position 28

133-134. (canceled)

### Claim 135 (depends on 57)

The multi-specific antigen binding molecule of claim 57, wherein the first antigen binding domain has reduced or insignificant or substantially no binding to Protein A, or does not detectably bind to Protein A.

### Claim 136 (depends on 57)

The multi-specific antigen binding molecule of claim 57, wherein the first antigen binding domain binds to Protein A with a KD of greater than 10−6 M.

### Claim 137 (depends on 57)

The multi-specific antigen binding molecule of claim 57, wherein the first antigen binding domain binds to CD3 with a KD of lower than 10 nM, e.g., lower than 9.5 nM, 9.0 nM, 8.5 nM, 8.0 nM, 7.5 nM, 7.0 nM, 6.5 nM, 6.0 nM, 5.5 nM, 5.0 nM, 4.5 nM, 4.0 nM, 3.5 nM, 3.0 nM, or lower.

### Claim 138

(canceled)

### Claim 139 (depends on 57)

The multi-specific antigen binding molecule of claim 57, wherein the antigen binding molecule has a serum half-life in a human or cynomolgus monkey of at least 3 days, e.g., at least 4 days, at least 5 days, at least 6 days, at least 7 days, at least 8 days, at least 9 days, at least 10 days, at least 11 days, at least 12 days, at least 13 days, at least 14 days, at least 15 days, at least 16 days, or longer.

### Claim 140

(canceled)

### Claim 141 (depends on 57)

The multi-specific antigen binding molecule of claim 57, wherein the first antigen binding domain binds to CD3 with a KD of lower than 7.0 nM, e.g., lower than 6.5 nM, 6.0 nM, 5.5 nM, 5.0 nM, 4.5 nM, 4.0 nM, 3.5 nM, 3.0 nM, or lower, and the antigen binding molecule has a serum half-life in a human or cynomolgus monkey of at least at least 5 days, e.g., at least 5.5 days, at least 6 days, at least 6.5 days, at least 7 days, at least 7.5 days, at least 8 days, at least 8.5 days, at least 9 days, at least 10 days, at least 11 days, at least 12 days, at least 13 days, at least 14 days, or longer.

### Claim at position 36

142-150. (canceled)

### Claim 151 (depends on 57)

A polynucleotide or multiple polynucleotides encoding the first VH and the first VL of the multi-specific antigen binding molecule claimed in claim 57.

### Claim at position 38

152-166. (canceled)

### Claim 167 (depends on 151)

A lipoplex, e.g., a lipid nanoparticle (LNP), comprising the polynucleotide or polynucleotides of claim 151.

### Claim 168 (depends on 151)

An expression cassette or multiple expression cassettes comprising one or more regulatory sequences operably linked to the polynucleotide or polynucleotides of claim 151.

### Claim 169 (depends on 151)

An expression vector or multiple expression vectors comprising one or more regulatory sequences operably linked to the polynucleotide or polynucleotides of claim 151.

### Claim at position 42

170-182. (canceled)

### Claim 183 (depends on 151)

A cell or population of cells, comprising the polynucleotide or polynucleotides of claim 151.

### Claim at position 44

184-190. (canceled)

### Claim 191 (depends on 57)

A pharmaceutical composition comprising one or more multi-specific antigen binding molecules claimed in claim 57, and a pharmaceutically acceptable carrier.

### Claim 192 (depends on 151)

A pharmaceutical composition comprising one or more polynucleotides of claim 151, and a pharmaceutically acceptable carrier.

### Claim at position 47

193-223. (canceled)

### Claim 224 (depends on 57)

A kit comprising one or more containers comprising one or more of the multi-specific antigen binding molecules claimed in claim 57.

### Claim at position 49

225-245. (canceled)

### Claim 246 (depends on 151)

A method of producing a multi-specific antigen binding molecule, the method comprising:
a) culturing a cell or population of cells of transformed with the polynucleotide or polynucleotides of claim 151 in a cell culture under conditions sufficient to express the multi-specific antigen binding molecules; and
b) isolating or purifying the antigen binding molecules from the cell culture.

### Claim at position 51

247-259. (canceled)

### Claim 260 (depends on 57)

A method of treating or preventing HIV in a human subject in need thereof, the method comprising administering to the subject an effective amount of one or more multi-specific antigen binding molecules of claim 57.

### Claim 261 (depends on 57)

A method of preventing or treating an HIV infection or an HIV-related disease comprising the steps of: identifying a patient in need of such prevention or treatment, and administering to said patient a first therapeutic agent comprising a therapeutically effective amount of one or more multi-specific antigen binding molecules of claim 57.

### Claim at position 54

262-349. (canceled)

### Claim 350 (depends on 57)

The multi-specific antigen binding molecule of claim 57, wherein the first VH and the first VL comprise the amino acid sequences of SEQ ID NOs: 50 and 56, respectively, or comprise amino acid sequences that are at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequences set forth, respectively: SEQ ID NOs: 50 and 56.

### Claim 351 (depends on 57)

The multi-specific antigen binding molecule of claim 57, wherein the first VH and the first VL comprise the amino acid sequences of SEQ ID NOs: 51 and 56, respectively, or comprise amino acid sequences that are at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identical to the amino acid sequences set forth, respectively: SEQ ID NOs: 51 and 56.
